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Acute promyelocytic leukemia (APL) was first 
described  as  an  independent  condition  in 
1957 (Hillestad, 1957) and presents clinically as 
a replacement of normal hematopoiesis in the   
bone marrow by an accumulation of promy­
elocytes, which are precursors of granulocytes.   
It is an aggressive disease associated with a high 
frequency of bleeding and thrombosis, and is 
rapidly fatal if not properly treated and managed. 
(Choudhry and DeLoughery, 2012; Kwaan and 
Huyck, 2010). The vast majority of APL cases are 
characterized by the fusion of the N­terminus of 
the promyelocytic leukemia protein (PML) to   
the C terminus of the retinoic acid receptor­a   
(RARa) transcription factor (Borrow et al., 1990; 
Chomienne et al., 1990; de Thé et al., 1990, 
1991; Longo et al., 1990; Alcalay et al., 1991; 
Kakizuka et al., 1991; Pandolfi et al., 1991) as a 
result of a balanced chromosomal translocation, 
t(15;17)(q22;q12;  Rowley  et  al.,  1977).  In 
variant forms of APL, RARa is fused to one   
of its alternative N­terminal partners includ­
ing promyelocytic leukemia zinc finger (PLZF), 
nucleophosmin  1  (NPM1),  nuclear  mitotic 
apparatus (NUMA), signal transducer and acti­
vator of transcription 5B (STAT5b), protein 
kinase,  cAMP­dependent,  regulatory,  type  I,   
 (PRKAR1A), FIP1­like 1 (FIP1L1), BCL6 
co­repressor  (BCOR)  and  oligonucleotide/
oligosaccharide­binding  fold  containing  2A 
(OBFC2A; Zelent et al., 2001; Redner, 2002;   
Catalano  et  al.,  2007;  Kondo  et  al.,  2008; 
Yamamoto et al., 2010; Won et al., 2013). Al­
though rare, these variant forms of APL have been 
very informative in elucidating the molecular 
mechanisms underlying the biological functions 
of the resulting fusion oncoproteins, especially 
PLZF­RARa, the most common and studied 
variant. This  review  is  focused  primarily  on 
PML­RARa  APL,  and  unless  clearly  stated, 
does not apply to the other translocations.
The molecular mechanism of transforma­
tion in APL has been extensively reviewed in 
numerous recent publications (Wang and Chen, 
2008; de Thé and Chen, 2010; de Thé et al., 2012). 
In brief, RARa is a nuclear receptor that in the 
absence of its ligand retinoic acid (RA) represses 
the transcription of target genes by recruiting 
co­repressors and histone deacetylases. Physio­
logical levels of RA convert RARa from a 
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Despite early promise however, it quickly became appar­
ent that ATRA alone was not going to provide a cure for 
APL. Patients that achieved CHR after ATRA monotherapy 
almost inevitably relapsed, some of them within only a few 
months of remission (the only exception to date consists of a 
small number of patients cured by liposomal ATRA mono­
therapy; Tsimberidou et al., 2006). This outcome offered a 
challenge to the understanding of leukemia treatment at the 
time, because it totally uncoupled initial response from long­
term outcome. The clue to understanding the inability of 
ATRA to eliminate APL came from the observation that pa­
tients in CHR after ATRA monotherapy retained a small 
number of APL cells, as indicated by the continued presence 
of PML­RARa mRNA (Warrell et al., 1991). This in turn led 
to the development of the concepts of minimal residual dis­
ease (MRD) and complete molecular remission (CMR) in 
APL and other malignancies. Indeed, currently, the elimina­
tion of MRD and the achievement of CMR (e.g., inability to 
detect the disease by a highly sensitive method such as PCR) 
is the goal of not only APL therapy (Grimwade et al., 2010), 
but treatment for acute lymphoblastic leukemia (Campana, 
2009) and chronic myeloid leukemia (CML; O’Hare et al., 
2012) as well.
Elimination of MRD and differentiation in APL therapy
That MRD reflects the persistence of LICs and predicts dis­
ease relapse is a concept that is now widely accepted. Though 
the cell surface markers, frequency, and pluripotent potential 
of LICs from different leukemias vary, they share several char­
acteristics including high self­renewal capability, replicative 
quiescence and intrinsic resistance to differentiation and cell 
death (Magee et al., 2012). In patients, ATRA therapy induces 
differentiation of APL blasts into functional granulocytes, but   
as stated above, in the vast majority of cases does not produce 
a long­term cure. However, subsequent studies have reported 
great synergy between ATRA, anthracyclines and/or ATO 
(discussed in detail below), with various combinations capable 
of achieving CMR and consequently long­term remissions in 
>90% of patients (Mandelli et al., 1997; Sanz et al., 1999, 
2004; Wang and Chen, 2008). Although ATO induces partial 
differentiation in vivo (Chen et al., 1997; Camacho et al., 
2000), in comparison with ATRA, ATO and anthracyclines 
are poor cellular differentiation agents. Collectively, these data 
suggest that APL blast differentiation on its own is insufficient 
to cure APL.
The  presence  of  LICs  in APL  and  their  resistance  to 
ATRA  monotherapy  has  also  been  confirmed  in  faithful 
mouse models using transplantation experiments that func­
tionally dissect LICs as cells capable of initiating disease when 
transferred to a syngeneic recipient (Brown et al., 1997; 
Grisolano et al., 1997; He et al., 1997, 1998). In an ex vivo 
study, Zheng et al. demonstrated that unlike ATO, ATRA 
does not abolish the self­renewal or engraftment potential of 
APL LICs (Zheng et al., 2007). Similarly, in an elegant in vivo 
study, Nasr et al. (2008) showed that low doses of ATRA that 
efficiently induce terminal differentiation are unable to target 
transcriptional  repressor  into  a  potent  activator,  driving   
expression of genes involved in myeloid differentiation. In 
contrast, PML­RARa remains an ineffectual transcriptional 
activator even in the presence of physiological RA levels. Ad­
ditionally, by forming heterodimers with PML, PML­RARa 
antagonizes the formation of nuclear bodies (NBs), which   
are macromolecular structures that regulate the P53 pathway 
among many other activities. Thus, after a classical model of 
leukemogenesis, PML­RARa is thought to simultaneously 
contribute two oncogenic hits in one: the block of differ­
entiation and the aberrant self­renewal of APL cells.
A variety of pharmacological interventions have proven 
effective against the disease. In particular, APL cells have been 
shown to be exquisitely sensitive to all­trans­RA (ATRA) 
and arsenic trioxide (ATO), which together with advances in 
chemotherapy (CT) and improvements in transfusion support 
therapy, have transformed the therapeutic landscape and con­
verted a highly fatal disease into a highly curable one (Wang 
and Chen, 2008). Although widely regarded as “targeted” 
therapies because of their selective effects on the PML­RARa 
fusion protein, both ATRA and ATO are naturally derived 
compounds. Their clinical application preceded the detailed 
scientific understanding of their mechanisms of action and 
drove subsequent efforts to determine the molecular and bio­
logical processes underlying their tremendous efficacy. In this 
review, we will critically summarize current knowledge in the 
field of APL therapeutics, with particular emphasis on two 
interconnected questions that remain vigorously debated: (1) 
what is the contribution of reversing the block of differentia­
tion of APL blasts vis­a­vis the elimination of the leukemia­
initiating cell (LIC) pool on the effective treatment of the 
disease, and (2) is the reversal of transcriptional repression or 
the proteolytic degradation of PML­RARa more important?
THE ATRA REVOLUTION
ATRA induces remission without cure
ATRA was first shown to be capable of inducing differentia­
tion in the cell line HL­60 and in primary APL specimens   
in vitro in 1981 (Breitman et al., 1981). The first description 
of ATRA as an APL therapy was subsequently published by a 
group from the Shanghai Institute of Hematology in 1988 
(Huang et al., 1988). The study documented the use of ATRA 
as a single agent in induction therapy for 24 patients, 16 of 
whom were receiving their first treatment, along with 8   
others  who  had  previously  undergone  CT.  Remarkably,   
all 24 patients achieved complete hematological remission 
(CHR) without developing bone marrow hypoplasia, with 
gains in coagulation parameters and a reduction in early mor­
tality, a startling improvement for the first phase of therapy. 
Subsequently, other groups confirmed these results (Castaigne 
et al., 1990; Warrell et al., 1991), and demonstrated that granu­
locytic differentiation was the major driver of CHR in vivo 
(Warrell et al., 1991). In fact, the effect of ATRA on the mor­
phology of APL cells was so striking that it subsequently be­
came known as “differentiation therapy.”JEM Vol. 210, No. 13  2795
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differentiation with the ancient Chinese Philosophy on the 
control of society, exemplified by the famous Confucius’ say­
ing: “If you use laws to direct the people, and punishments to 
control them, they will merely try to evade the laws, and will 
have no sense of shame. But if by virtue you guide them, and 
by the rites you control them, there will be a sense of shame 
and of right.”
Uncoupling PML-RARa transactivation and degradation
The molecular mode of action of ATRA remains a subject of 
intense research. At pharmacological doses, ATRA converts 
PML­RARa from a transcriptional repressor to a transcrip­
tional activator and induces its proteolysis (Wang and Chen, 
2008). Under most conditions these two processes are tightly 
coupled, a mechanism that applies not only to PML­RARa 
and RA receptors, but also to other nuclear receptors includ­
ing estrogen receptor, thyroid hormone receptor and peroxi­
some proliferator­activated receptors (Nawaz et al., 1999; 
Zhu et al., 1999; Hauser et al., 2000; Kopf et al., 2000; 
Tanaka et al., 2001). Indeed linkage of ligand­dependent   
activation and subsequent degradation is a general feature of 
nuclear  receptor  signaling,  providing  a  negative  feedback 
loop that ensures that signaling is shut off once the ligand is 
no longer present. In the case of PML­RARa, spontaneous   
mutations that render APL cells resistant to ATRA in patients   
LICs or clear the disease. Intriguingly, high doses of ATRA 
reduced LIC frequency, but did not eradicate LICs, whereas 
the combination of ATRA and cAMP enhanced the effect on 
LICs (Guillemin et al., 2002; Nasr et al., 2008). Collectively, 
these observations underscore the significance of LIC eradi­
cation in curing APL.
Despite the inability of ATRA to cure APL as a mono­
therapy, it is important to note that it remains a mainstay of 
APL  treatment  precisely  because  of  its  pro­differentiation   
effects (albeit in combination with CT or ATO with which it 
can synergize to eliminate LICs and MRD; Fig. 1). In fact, a 
recent recommendation from an expert European panel states 
that ATRA should be administered in cases where APL is sus­
pected, even if definitive diagnosis based on karyotyping or 
other molecular methods is not immediately available (Sanz 
et al., 2009). The leading cause of early death in APL is bleed­
ing caused by a coagulopathy driven by procoagulant and   
fibrinolytic factors (e.g., Annexin A2 and tissue factor) present 
in APL blasts and blast­derived microparticles (Koyama et al., 
1994; Menell et al., 1999). Proapoptotic agents such as ATO and 
CT can promote the release of these factors, thereby accentuat­
ing the problem (Sanz and Montesinos, 2010). ATRA­driven 
differentiation, on the other hand, minimizes the release of 
these factors by converting APL blasts into mature granulo­
cytes. Indeed, Wang and Chen (2008) compared ATRA induced 
Figure 1.  Elimination of leukemic blasts and LICs is necessary for definitive cure of APL. LICs posses high self-renewal capability and give rise to 
leukemic blasts that form the bulk of the disease (middle). Both ATRA and ATO promote remission of disease by targeting leukemic blasts. Pharmacologi-
cal doses of ATRA predominantly drive differentiation of leukemic blasts, but are unable to efficiently eliminate LICs that can drive disease relapse (right). 
In contrast, ATO induces both apoptosis and differentiation of leukemic blasts and can also target LICs and is therefore more effective that ATRA as a 
monotherapy (left). ATRA acts synergistically with ATO and/or CT, and these combination therapies definitively cure APL in the vast majority of cases 
(dashed arrow).2796 The molecular mechanisms underlying APL cure | dos Santos et al.
A recent phase II study similarly reported a CR rate of 85% 
and a 5­yr DFS of 66.7% for ATO as a single agent, though a 
relatively high number of deaths caused by differentiation 
syndrome (13.2%) were observed (Ghavamzadeh et al., 2011).
On the basis of these striking data, the mechanism of   
action of ATO was put under intense scrutiny. ATO was 
shown to degrade PML­RARa via its PML moiety further 
reinforcing the idea that APL is addicted to the PML­RARa 
oncoprotein (Lallemand­Breitenbach et al., 2012). We now 
know that ATO binds directly to PML and PML­RARa via 
two cysteines (C212/213) in the B2 domain and induces oxi­
dation of these residues and the formation of intermolecular 
disulfide bonds (Jeanne et al., 2010; Zhang et al., 2010). This 
is followed by sumoylation of a lysine residue (K160) and the 
subsequent reorganization of PML/PML­RARa from a dif­
fuse/microspeckled nuclear pool into matrix­associated mac­
romolecular structures termed PML­nuclear bodies (NB; 
Jeanne et al., 2010). It is within these structures that PML/
PML­RARa is polyubiquitinated by the Sumo­dependent 
E3 ubiquitin ligase RNF4 and subsequently degraded by the 
proteasome  (Lallemand­Breitenbach  et  al.,  2008;  Tatham   
et al., 2008; Fig. 2). The few characterized cases of ATO resis­
tance displayed missense mutations in the B2 domain of PML­
RARa, rendering the oncoprotein resistant to sumoylation 
and degradation (Goto et al., 2011) and confirming the im­
portance of this domain for the efficacy of ATO in APL.
It should be noted that ATO can also induce degradation 
of PML/PML­RARa not only through direct binding, but 
also indirectly through its effects on the mitochondria and 
generation of ROS. ROS promotes oxidation of PML and 
its assembly into NBs, and numerous compounds that induce 
ROS production have shown activity against APL. Alpha   
tocopheryl succinate (­TOS) induces apoptosis of APL cells 
and clearance of disease in a murine APL model by directly 
targeting the mitochondrial respiratory chain, leading to   
accumulation of ROS and at least partial degradation of 
PML­RARa (dos Santos et al., 2012). Likewise, paraquat, a 
dangerous poison that produces massive amounts of ROS 
(Morán et al., 2010), is highly effective at degrading PML­
RARa and clearing APL in the mouse (Jeanne et al., 2010). 
Notably, anthracyclines generate ROS, which may partially 
explain their increased efficacy in APL in comparison with 
other types of AML.
ATO VERSUS ATRA
The evidence from mice and men firmly demonstrates that 
whereas both ATO and ATRA target the PML­RARa on­
coprotein for proteolysis, only ATO is superior at achieving 
a complete cure, as a monotherapy, by eliminating residual 
LICs. One possible explanation of these findings is that ATO 
is  simply  more  effective  at  degrading  PML­RARa  than 
ATRA. It should be noted that ATRA, which is typically 
administered orally and is rapidly metabolized, may not reach 
optimal concentration in patient serum to ensure killing of all 
APL cells. Indeed when administered intravenously via injec­
tion of a liposomal­encapsulated preparation, and thereby 
or in vitro almost invariably occur in the ligand­binding   
domain (LBD; Raelson et al., 1996; Rosenauer et al., 1996; 
Marasca et al., 1999; Côté et al., 2000). Additionally, targeted 
mutational analysis has revealed that alterations to either the 
ligand­binding domain or the AF2 domain of PML­RARa 
that abolish the transactivation of PML­RARa by ATRA, 
also abolish receptor catabolism (Zhu et al., 1999). Interest­
ingly, ATRA resistance mediated by LBD mutations can be 
at least partially reversed by genetic or pharmacological acti­
vation of the lysine demethylase PHF8, which serves as an 
essential co­activator of PML­RARa transcription after phar­
macological administration of ATRA (Arteaga et al., 2013).
Several groups have devoted considerable effort to un­
coupling transactivation and proteolysis of PML­RARa on 
the one hand, and APL blast differentiation and disease   
clearance in vivo on the other. Low doses of ATRA that   
efficiently induce terminal differentiation are unable to target 
LICs or clear the disease in mouse models of APL (Nasr et al., 
2008). Additionally, PML­RARa Ser873, a residue that is 
phosphorylated by protein kinase A (PKA) and was shown to 
be important for ATRA­mediated PML­RARa degradation 
but not transactivation, is essential for ATRA­mediated clear­
ance of APL (Nasr et al., 2008), (note however, that the 
equivalent residue in RARa, Ser369, has been implicated in 
transcriptional activation of wild­type RARa (Gaillard et al., 
2006)). Finally, in a recent issue of The Journal of Experimental 
Medicine, Ablain et al. (2013) showed that the synthetic reti­
noids  Etretinate  and  NRX195183,  compounds  that  drive 
transcription of PML­RARa–dependent genes at levels com­
parable to ATRA, but do not cause the oncoprotein to be 
degraded, induce granulocytic differentiation at levels com­
parable to ATRA, but are far less effective at clearing the dis­
ease in vivo. Viewed along with clinical observations and 
experimental data discussed earlier, these results suggest that: 
(1) transcriptional transactivation of PML­RARa is the main 
driver of differentiation; (2) differentiation alone is not suffi­
cient to induce disease clearance; and (3) the clinical efficacy 
of ATRA is a result of its ability to link transactivation of 
PML­RARa and its subsequent proteolysis.
CURATIVE MONOTHERAPY
The first definitive evidence of ATOs efficacy in APL again 
came from a well­controlled study conducted in Shanghai, in 
which ATO remarkably induced CR in 9 out of 10 relapsed 
patients, most of whom had already received ATRA therapy 
(Shen et al., 1997). The only patient that did not achieve CR 
presented with a loss of PML­RARa during the course of 
initial treatment. In contrast to ATRA, ATO monotherapy 
produced long­term cures, even when used in the setting of 
relapsed disease (Shen et al., 1997; Soignet et al., 1998). Pa­
tients treated with ATO as a single agent in frontline therapy 
presented  a  3­yr  disease­free  survival  (DFS)  rate  of  87% 
(Mathews et al., 2006) and a 5­yr DFS rate of 80% (Mathews 
et al., 2010). When this analysis was restricted to the major 
group of patients considered to have a lower risk of relapse, 
the DFS at 3 and 5 yr was 100% (Mathews et al., 2006, 2010). JEM Vol. 210, No. 13  2797
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Sp1 (Chou et al., 2005). However, to date, these studies have 
been performed in vitro, and it remains to be determined 
which of these mechanisms contribute to LIC elimination 
and which function predominantly in removing the bulk 
APL blast population during ATO treatment.
ATO/ATRA COMBINATION THERAPY
While the discovery of the efficacy of ATRA and ATO   
in APL was originally based on clinical studies, preclinical   
studies in mouse models of APL proved that ATRA and 
ATO treatments are synergistic and highly curative. Notably, 
in  vivo  mouse  modeling  experiments  proved  decisive  in   
reversing the erroneous notion that ATRA and ATO would 
oppose each other, an idea based on misleading in vitro   
experiments using primary APL cells and cell lines (Shao   
et al., 1998; Lallemand­Breitenbach et al., 1999; Jing et al., 
2001; Rego et al., 2000). The superior effectiveness of com­
bining ATRA and ATO was initially demonstrated by two 
studies using transgenic mouse models of PML­RARa APL 
(Lallemand­Breitenbach et al., 1999; Rego et al., 2000). 
PLZF­RARa associated APL in the mouse did not respond 
to this combination (see below; Rego et al., 2000). Critically, 
these studies emphasized the relevance of ATO and ATRA 
converging on the degradation of PML­RARa via targeting 
the  PML  and  RARa  moieties,  respectively.  Later  clinical   
reports began to point to the synergistic interaction of this 
combination (Kennedy et al., 2000; Au et al., 2002; Visani   
et al., 2003) and its benefit was subsequently demonstrated   
in a randomized study in both short­ (Shen et al., 2004) and 
long­term analyses (Hu et al., 2009). Most recently, ATRA 
bypassing initial hepatic metabolism, ATRA may be more 
effective and sufficient to cure some APL patients. However, 
another intriguing possibility is that, in addition to degrading 
PML­RARa, ATO also targets other pathways that are es­
sential for LIC maintenance and self­renewal. In APL cells, 
ATRA degrades PML­RARa, restoring the function of the 
remaining wild­type PML allele, whereas ATO targets both 
PML­RARa and PML for degradation. Recent evidence   
has shown that PML regulates hematopoietic stem cell main­
tenance via mTOR and peroxisome proliferator­activated   
receptor­d (PPAR­d)–fatty­acid oxidation (FAO) pathways 
(Ito et al., 2008, 2012). Likewise, PML regulates maintenance 
of LICs transformed by the presence of the CML oncogene 
BCR­ABL, which rapidly exhaust upon loss of PML (Ito   
et al., 2008). Ablation of PML in APL LICs treated with 
ATO may have similar effects, driving them from their qui­
escent state and promoting loss of self­renewal capabilities 
and clearance.
Other molecular pathways triggered by ATO likely syn­
ergize with its effects on PML­RARa and PML. At clinically 
relevant concentrations, ATO can promote apoptosis in APL 
cells by several mechanisms. Oxidative stress triggered by 
ATO can reverse the inhibitory effect of glutathione transfer­
ase P1­1 (GSTP1­1) on the c­Jun N­terminal kinase (JNK) 
proapoptotic signaling cascade (Bernardini et al., 2006). ATO 
treatment can also induce expression of caspase­10 through 
its effects on chromatin at the Caspase-10 locus (Li et al., 
2002). Likewise, treatment of the APL cell line NB4 with 
ATO has been reported to repress expression of hTERT, 
MYC, and C17 through oxidation of the transcription factor 
Figure 2.  Mechanisms of proteolysis of 
PML-RARa by ATRA and ATO. ATRA  
induces degradation of RARa and PML-RARa 
via the RARa moiety. ATO induces degradation 
of PML and PML-RARa via the PML moiety.2798 The molecular mechanisms underlying APL cure | dos Santos et al.
BEYOND APL
Two important themes have emerged from our therapeutic 
conquest of APL and the subsequent analysis of the molecular 
basis underpinning the remarkable clinical efficacy of ATRA 
and ATO: first, cure requires the elimination of the bulk of 
the tumor, as well as a small residual population of cells capa­
ble of self­renewal and disease reinitiation; Second, activation   
of pathways that results in degradation of key driving onco­
proteins might represent a highly effective method for tar­
geting cancer cells when/if the cancer cell is addicted to its 
continued expression.
That ATO is curative in >70% of APL patients is likely a 
combination of its effects on both the bulk blast population, 
via degradation of PML­RARa; and LICs, at least in part   
via PML­dependent/PML­RARa–independent mechanism. 
Though ATO has shown poor efficacy as a single agent in 
many other malignancies, its effects on self­renewal of quies­
cent cells may potentiate the effects of other therapeutic mo­
dalities that are able to effectively eliminate rapidly dividing 
cells. Indeed, in this role, ATO has shown promise in at least 
two other hematopoietic malignancies, namely adult T cell 
leukemia/lymphoma driven by HTLV­1 infection (in combi­
nation with interferon) and CML (in combination with tyro­
sine kinase inhibitor, Fig. 3). In both cases, ATO is able to 
induce at least partial proteolysis of the driving oncoprotein 
(the viral transactivator Tax in HTLV­1 and the Bcr­Abl fu­
sion protein in CML) and, importantly, transplantation exper­
iments in mouse models have revealed that ATO treatment can 
result in profound inhibition of LIC function (Ito et al., 2008; 
El Hajj et al., 2010). In the case of CML, these effects are   
also due to ATO’s ability to target PML, as shown by genetic 
inactivation of the Pml gene itself (Ito et al., 2008).
Moving beyond PML, numerous other cellular pathways 
have been shown to be key for LIC maintenance. The poly­
comb group protein Bmi­1 is essential for the proliferation 
and self­renewal of both hematopoietic stem cells (HSCs) and 
LICs. Genetic deletion of Bmi-1 in a HoxA9/Meis1a trans­
duction model of AML has no effect on the primary disease, 
but abrogates its ability to be transplanted to secondary recipi­
ents (Lessard and Sauvageau, 2003). Conversely, overexpres­
sion of Bmi-1 can cooperate with Bcr­Abl in promoting 
the transformation of CML B­lymphoid progenitors into   
self­renewing LICs in B cell acute lymphoblastic leukemia   
(Sengupta et al., 2012).
LICs have recently been shown to depend on high levels 
of Bcl2 and oxidative phosphorylation for their energy needs. 
Although these cells possess low levels of ROS, at least in part 
mediating their resistance to ROS­inducing chemotherapy, 
they can be efficiently targeted by pharmacological inhibition   
of Bcl2 (Lagadinou et al., 2013). LICs also appear to be depen­
dent on elevated Wnt–B­catenin and mTOR signaling, poten­
tially providing other therapeutic targets for their elimination 
(Wang et al., 2010). The Wnt–B­catenin pathway is dispens­
able for maintenance of normal HSCs, but is essential for 
both the formation and maintenance of LICs (Wang et al., 
2010). Hyperactivation of mTOR signaling leads to exhaustion 
plus ATO was shown to be at least as efficacious as the stan­
dard protocol of ATRA plus idarubicin in non–high risk 
patients (2 yr DFS of 97% versus 86.7% for ATRA plus ATO 
and ATRA plus idarubicin, respectively; Lo­Coco et al., 2013). 
That ATO and ATRA synergize against APL and are among 
the most successful leukemia treatments are now widely   
accepted as facts (Sanz et al., 2009; Tallman and Altman, 
2009; Sanz and Lo­Coco, 2011; Mi et al., 2012).
ONCOPROTEIN DEGRADATION MAY NOT SUFFICE
Although APL associated with t(11;17)(q23;q21) chromo­
somal translocation is a rare subtype, the study of its associ­
ated fusion protein PLZF­RARa and its comparison with 
PML­RARa, have offered important insights into the mech­
anisms underlying the pathogenesis of APL (He et al., 1998). 
APL patients harboring the t(11;17)(q23;q21) chromosomal 
translocation have a significantly worse prognosis than pa­
tients with t(15:17) APL and show little or no response to either 
ATO or ATRA (Licht et al., 1995; Koken et al., 1999). Not 
surprisingly ATO is unable to induce the proteolysis of 
PLZF­RARa in vitro or in vivo (Koken et al., 1999; Rego 
et al., 2000). In contrast, pharmacological doses of ATRA   
do produce efficient degradation of PLZF­RARa and are suf­
ficient to induce phenotypic differentiation of APL blasts,   
albeit  less  effectively  than  in  PML­RARa  leukemic  cells 
(Koken et al., 1999; Rego et al., 2000; Nasr et al., 2008). 
However, unlike in t(15;17) APL, ATRA treatment does not 
restore normal hematopoiesis or induce temporary remission 
in either humans or mice with PLZF­RARa APL (Licht   
et al., 1995; Rego et al., 2000; Nasr et al., 2008). Indeed, 
PLZF­RARa–transformed cells retain the ability to grow, 
even in the absence of detectable levels of PLZF­RARa   
protein (Rego et al., 2000), demonstrating that oncogene degra­
dation may not be an effective strategy in all malignancies 
(Ablain et al., 2011). Notably, ATRA in combination with 
histone deacetylase inhibitors has shown efficacy in cell lines, 
transgenic mouse models, and some patients (Warrell et al., 
1998; He et al., 2001), suggesting that PLZF­RARa estab­
lishes an aberrant chromatin state that is maintained indepen­
dently of the continued presence of the fusion protein. This, 
in turn, implies that (in the case of PLZF­RARa) the sole 
degradation of the oncoprotein does not suffice, perhaps due 
to its long­lasting effects on chromatin remodeling toward 
transcriptional repression, and that these effects have to be 
reversed for complete remission and disease eradication to 
occur. Nevertheless, experiments using transgenic models 
where the PLZF­RARa oncoprotein can be genetically ab­
lated are needed to fully understand the mechanisms underly­
ing the apparent lack of oncogene­addiction in PLZF­RARa 
APL. Furthermore, in human t(11;17)(q23;q21) APL, the   
reciprocal product RARa­PLZF is also expressed and can 
contribute to the block in hematopoietic differentiation and 
the unresponsiveness to therapy, as shown in dual transgenic 
model  that  coexpress  the  PLZF­RARa  and  RARa­PLZF   
fusion genes (He et al., 2000).JEM Vol. 210, No. 13  2799
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